New Molecularly Targeted Therapies for Glioblastoma Multiforme

摘要: Glioblastoma multiforme (GBM) is the most malignant brain tumor in adults, exhibiting high mortality. Standard therapy (surgery, radiotherapy and chemotherapy with temozolomide) has only limited effectiveness. The progress genomics regarding GBM, detection of new markers oncogenesis‚ abnormalities signalling pathways, microenvironment, pathological angiogenesis over past decade are briefly discussed. role novel prognostic this review biomarkers (isocitrate dehydrogenases 1 2, CpG island methylator phenotype, promoter methylation status MGMT (O-6- methylguanine-methyltransferase) gene) also New targeted therapeutic approaches classified into several functional subgroups, such as inhibitors growth factors their receptors, proteins intracellular signaling epigenetic gene-expressing mechanisms, angiogenesis, imunotherapy vaccines. Finally possibilities for GBM treatment summarized review. common primary an incidence 3-4/100,000/year (1). extremely invasive difficult to treat surgically, characterized by intense aberrant vascularization resistance (RT) chemotherapy. current standard care patients newly diagnosed neurosurgery, followed fractionated external beam RT systemic temozolomide (2). median survival 12.1-14.6 months (3) 3-5% survive longer than 3 years (4). 10 years, revealed pathways a diversity mutated genes. importance microenvironment especially have been studied. use knowledge on molecular genetic levels could lead individual patient analysis management. This focuses facilitated these findings.